Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”

Rosella Levaggi and Paolo Pertile

Applied Health Economics and Health Policy, 2020, vol. 18, issue 3, No 16, 455-456

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-020-00557-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:18:y:2020:i:3:d:10.1007_s40258-020-00557-w

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-020-00557-w

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().